Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

See Remarks

General Counsel

Chief Operating Officer

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted ca...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-03	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-05-03	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-10	Premium	acquired	Premium	Premium	Premium	-
2024-04-10	Premium	sold	Premium	Premium	Premium	-
2024-04-10	Premium	sold	Premium	Premium	Premium	See Remarks
2024-04-10	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-27	Premium	sold	Premium	Premium	Premium	General Counsel
2024-03-18	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-18	Premium	sold	Premium	Premium	Premium	General Counsel
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-18	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-12	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-03-12	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-11	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-11	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-22	Premium	sold	Premium	Premium	Premium	General Counsel
2024-01-08	Premium	sold	Premium	Premium	Premium	See Remarks
2024-01-02	Premium	sold	Premium	Premium	Premium	See Remarks

RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RVMD